The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

Although comorbidity burden had no prognostic significance in patients with HCC, older age was significantly associated with worse overall survival.

Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...